A Study to Evaluate the Safety of mRNA-0184 in Participants With Heart Failure
Completed · Phase 1 · Has a placebo group
Conditions studied: Chronic Heart Failure
In brief
The primary objective of this study is to evaluate the safety and tolerability of single and multiple doses at escalating dose levels of mRNA-0184.
Key facts
- Study ID
- NCT05659264
- Run by
- ModernaTX, Inc.
- People needed
- 48
- Starts
- 2022-12-05
- Expected to finish
- 2024-12-17
- Last updated by the study team
- 2025-03-17
Who can join
Age: 18 and older. Sex: any. Healthy volunteers: not accepted.
Where it is running
- Cardiology PC — Birmingham, Alabama, United States
- University of Alabama at Birmingham: The Kirklin Clinic — Birmingham, Alabama, United States
- University of Florida — Gainesville, Florida, United States
- Jacksonville Center For Clinical Research - ERN - PPDS — Jacksonville, Florida, United States
- Tennessee Center for Clinical Trials — Tullahoma, Tennessee, United States
- Uniwersytecki Szpital Kliniczny w Poznaniu — Poznan, Greater Poland Voivodeship, Poland
- Uniwersytecki Szpital Kliniczny im. Jana Mikulicza Radeckiego we Wroclawiu — Wroclaw, Lower Silesian Voivodeship, Poland
- Uniwersytecki Szpital Kliniczny w Bialymstoku — Bialystok, Podlaskie Voivodeship, Poland
- Gornoslaskie Centrum Medyczne im. prof. Leszka Gieca Slasiego Uniwersytetu Medycznego w Katowicach — Katowice, Silesian Voivodeship, Poland
- Ninewells Hospital & Medical School — Dundee, Angus, United Kingdom
- Addenbrooke's Hospital — Cambridge, Cambridgeshire, United Kingdom
- University College Hospital — London, City of London, United Kingdom
- Derriford Hospital — Plymouth, Devon, United Kingdom
- The Royal Liverpool University Hospital — Liverpool, United Kingdom
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.